SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

WEEDCOIN CRYPTO is actively trending, fueled by its strong, culture-first community on Solana, which champions a long-term "Bongterm" vision. The token is celebrated as the digital representation of global cannabis culture, with ongoing discussions emphasizing its positive community energy and potential for future growth. Enthusiasts are rallying around the mantra "Like Bitcoin But Way Higher," highlighting shared belief and patience.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is trending as news circulates about its acquisition of VLX-1005 and advancements for its lead candidate, tecarfarin, including manufacturing progress and a pivotal Phase 3 trial collaboration with Abbott. The investment community is actively discussing tecarfarin's potential as a next-generation anticoagulant with Fast Track designation for a significant market, yet considerable skepticism persists regarding the company's financial strategy and alleged bot-driven social media activity.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is trending following news of a multi-billion dollar government investment aimed at securing domestic critical mineral supply chains. This substantial funding, structured as an equity stake and additional financing, has sparked significant community excitement, with many anticipating a considerable increase in valuation and discussing the potential for a short squeeze. The development reinforces broader efforts to establish an integrated mine-to-magnet supply chain and reduce reliance on foreign sources for essential materials.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. is trending amidst widespread controversy following a recent incident involving federal agents and an American citizen in Minneapolis, igniting fierce debate within the community regarding civil liberties and law enforcement tactics. Many are condemning the event as an unjustified killing, while others defend the actions of federal agents against alleged interference, amplifying the polarized political discussion surrounding the company. This comes as broader market anxieties, including potential government shutdown threats and international trade tensions, contribute to heightened investor attention.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network Inc. ($BNAI) is experiencing intense trending activity driven by a significant short squeeze, with community chatter focusing on a low share float and high borrow rates creating immense pressure on short positions. Discussion among traders centers on the stock's potential for extended gains as short sellers face considerable challenges, drawing comparisons to other historical squeeze events.

Zoracles

Zora Crypto is currently trending as the community anticipates a significant market reversal and a potential altcoin season, fueled by upcoming legislative developments like the Clarity Act and shifts in monetary policy. Investors are actively accumulating tokens, expressing both excitement for its long-term potential and patience through recent volatility, highlighting its role in the creator economy on Coinbase's Base ecosystem and its positioning in real-world asset tokenization.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is a top trending stock as the community eagerly awaits the release of critical 3-year durability data for its Duchenne gene therapy, Elevidys. Discussions are highly polarized, with many anticipating robust results to ignite a substantial short squeeze and confirm the company's long-term value, while others remain wary of past market reactions and ongoing regulatory scrutiny. This highly anticipated data is widely considered a pivotal moment, shaping expectations for future market performance and potential strategic interest.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as its US subsidiary submitted a consolidated deep-seabed mining application to NOAA, a critical step enabled by updated regulations that expand its potential recovery area. The community is highly bullish, driven by the perceived national security imperative to secure essential critical minerals and reduce foreign supply chain dependence. Investors are actively discussing the anticipation of rapid permit approval, strong government backing, and the potential for a significant short squeeze.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroup is trending as its ongoing transformation gains momentum, driven by proactive cost-cutting measures and CEO-led reorganization efforts that leverage AI for efficiency. This strategic overhaul, coupled with recent analyst upgrades and progress in resolving regulatory oversight, is bolstering investor confidence in the bank's long-term profitability. While discussions include potential impacts from proposed credit card rate caps, the community is actively debating Citi's potential for sustained growth and its ventures into digital assets.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is actively discussed following compelling Phase 1 data for its oral ITK inhibitor, soquelitinib, in atopic dermatitis, which some believe positions it favorably against existing treatments due to its efficacy and safety profile. This has fueled a divided community, with many anticipating substantial future appreciation and potential partnerships, while others remain cautious, citing the company's early clinical stage and recent capital raise as reasons for skepticism regarding its valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 50 Day Moving Average - Time to Sell?

Seres Therapeutics (NASDAQ:MCRB) Share Price Passes Below 50-Day Moving Average - What's Next...

Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving Average - Here's Why

Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 50-Day Moving Average - Here's Why...

3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround

Beaten-down biotech stocks like ALT, IBRX and MCRB are eyeing a 2026 rebound as FDA alignment, pipeline progress and approvals fuel optimism.

Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 50 Day Moving Average - Should You Sell?

Seres Therapeutics (NASDAQ:MCRB) Stock Crosses Below Fifty Day Moving Average - Should You Sell...

Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Above 50 Day Moving Average - Here's What Happened

Seres Therapeutics (NASDAQ:MCRB) Stock Passes Above Fifty Day Moving Average - What's Next...

Seres Therapeutics (NASDAQ:MCRB) Stock Passes Below 50 Day Moving Average - Here's What Happened

Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below Fifty Day Moving Average - Here's Why...

Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below Fifty Day Moving Average - Should You Sell?

Seres Therapeutics (NASDAQ:MCRB) Share Price Passes Below 50-Day Moving Average - Time to Sell...

Insider Selling: Seres Therapeutics (NASDAQ:MCRB) Insider Sells 1,257 Shares of Stock

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) insider Matthew Henn sold 1,257 shares of the business's stock in a transaction on Saturday, November 15th. The stock was sold at an average...

Seres Therapeutics (NASDAQ:MCRB) Share Price Crosses Below Fifty Day Moving Average - Time to Sell?

Seres Therapeutics (NASDAQ:MCRB) Share Price Crosses Below 50 Day Moving Average - Here's What Happened...

All You Need to Know About Seres Therapeutics (MCRB) Rating Upgrade to Buy

Seres Therapeutics (MCRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

$MSFT

$AAPL

$TSLA

$META

Earnings season is heating up, and several major companies report next week, including Microsoft, Apple, Tesla, and Meta. Which are you most excited for?

Which earnings report are you most excited for next week? 
 
Drop a comment for others.

MCRB
Seres Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MCRB News

MCRBSeres Therapeutics Inc